Viral Etiology of Acute Gastroenteritis in <2-Year-Old US Children in the Post-Rotavirus Vaccine Era.


Journal

Journal of the Pediatric Infectious Diseases Society
ISSN: 2048-7207
Titre abrégé: J Pediatric Infect Dis Soc
Pays: England
ID NLM: 101586049

Informations de publication

Date de publication:
06 Nov 2019
Historique:
received: 08 11 2017
accepted: 02 08 2018
pubmed: 6 9 2018
medline: 31 3 2020
entrez: 6 9 2018
Statut: ppublish

Résumé

The rotavirus disease burden has declined substantially since rotavirus vaccine was introduced in the United States in 2006. The aim of this study was to determine the viral etiology of acute gastroenteritis (AGE) in US children aged <2 years. The New Vaccine Surveillance Network (NVSN) of geographically diverse US sites conducts active pediatric population-based surveillance in hospitals and emergency departments. Stool samples were collected from children aged <2 years with symptoms of AGE (n = 330) and age-matched healthy controls (HCs) (n = 272) between January and December 2012. Samples were tested by real-time reverse-transcriptase polymerase chain reaction assays {adenovirus (type 40 and 41), norovirus, parechovirus A, enterovirus, sapovirus, and astrovirus} and an enzyme immunoassay (rotavirus). All samples that tested positive were genotyped. Detection rates of pathogens in children with AGE versus those of HCs were, respectively, 23.0% versus 6.6% for norovirus (P < .01), 23.0% versus 16.0% for adenovirus (P = .08), 11.0% versus 16.0% for parechovirus A (P = .09), 11.0% versus 9.0% for enterovirus (P = .34), 7.0% versus 3.0% for sapovirus (P = .07), 3.0% versus 0.3% for astrovirus (P = .01), and 3.0% versus 0.4% for rotavirus (P = .01). A high prevalence of adenovirus was detected at 1 surveillance site (49.0% for children with AGE and 43.0% for HCs). Norovirus GII.4 New Orleans was the most frequently detected (33.0%) norovirus genotype. Codetection of >1 virus was more common in children with AGE (16.0%) than in HCs (10.0%) (P = .03). Norovirus, astrovirus, sapovirus, and rotavirus were detected significantly more in children with AGE than in HCs, and norovirus was the leading AGE-causing pathogen in US children aged <2 years during the year 2012.

Sections du résumé

BACKGROUND BACKGROUND
The rotavirus disease burden has declined substantially since rotavirus vaccine was introduced in the United States in 2006. The aim of this study was to determine the viral etiology of acute gastroenteritis (AGE) in US children aged <2 years.
METHODS METHODS
The New Vaccine Surveillance Network (NVSN) of geographically diverse US sites conducts active pediatric population-based surveillance in hospitals and emergency departments. Stool samples were collected from children aged <2 years with symptoms of AGE (n = 330) and age-matched healthy controls (HCs) (n = 272) between January and December 2012. Samples were tested by real-time reverse-transcriptase polymerase chain reaction assays {adenovirus (type 40 and 41), norovirus, parechovirus A, enterovirus, sapovirus, and astrovirus} and an enzyme immunoassay (rotavirus). All samples that tested positive were genotyped.
RESULTS RESULTS
Detection rates of pathogens in children with AGE versus those of HCs were, respectively, 23.0% versus 6.6% for norovirus (P < .01), 23.0% versus 16.0% for adenovirus (P = .08), 11.0% versus 16.0% for parechovirus A (P = .09), 11.0% versus 9.0% for enterovirus (P = .34), 7.0% versus 3.0% for sapovirus (P = .07), 3.0% versus 0.3% for astrovirus (P = .01), and 3.0% versus 0.4% for rotavirus (P = .01). A high prevalence of adenovirus was detected at 1 surveillance site (49.0% for children with AGE and 43.0% for HCs). Norovirus GII.4 New Orleans was the most frequently detected (33.0%) norovirus genotype. Codetection of >1 virus was more common in children with AGE (16.0%) than in HCs (10.0%) (P = .03).
CONCLUSIONS CONCLUSIONS
Norovirus, astrovirus, sapovirus, and rotavirus were detected significantly more in children with AGE than in HCs, and norovirus was the leading AGE-causing pathogen in US children aged <2 years during the year 2012.

Identifiants

pubmed: 30184153
pii: 5090096
doi: 10.1093/jpids/piy077
doi:

Substances chimiques

Rotavirus Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

414-421

Subventions

Organisme : NCIRD CDC HHS
ID : U01 IP001049
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001050
Pays : United States
Organisme : NCIRD CDC HHS
ID : U01 IP001063
Pays : United States

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Ferdaus Hassan (F)

Department of Pathology and Laboratory Medicine, Children's Mercy Hospitals and Clinics, Kansas City, Missouri.
University of Missouri, School of Medicine, Kansas City.

Neena Kanwar (N)

Department of Pathology and Laboratory Medicine, Children's Mercy Hospitals and Clinics, Kansas City, Missouri.

Christopher J Harrison (CJ)

University of Missouri, School of Medicine, Kansas City.
Division of Infectious Diseases, Children's Mercy Hospitals and Clinics, Kansas City, Missouri.

Natasha B Halasa (NB)

Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.

James D Chappell (JD)

Department of Pediatrics, Vanderbilt University School of Medicine, Nashville, Tennessee.

Janet A Englund (JA)

Department of Pediatrics, Seattle Children's Hospitals, Washington.

Eileen J Klein (EJ)

Department of Pediatrics, Seattle Children's Hospitals, Washington.

Geoffrey A Weinberg (GA)

University of Rochester School of Medicine and Dentistry, New York.

Peter G Szilagyi (PG)

University of Rochester School of Medicine and Dentistry, New York.
Department of Pediatrics, University of California at Los Angeles.

Mary E Moffatt (ME)

University of Missouri, School of Medicine, Kansas City.
Division of Emergency Medicine, Children's Mercy Hospitals and Clinics, Kansas City, Missouri.

M Steven Oberste (MS)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

William A Nix (WA)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Shannon Rogers (S)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Michael D Bowen (MD)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Jan Vinjé (J)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Mary E Wikswo (ME)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Umesh D Parashar (UD)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Daniel C Payne (DC)

Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia.

Rangaraj Selvarangan (R)

Department of Pathology and Laboratory Medicine, Children's Mercy Hospitals and Clinics, Kansas City, Missouri.
University of Missouri, School of Medicine, Kansas City.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH